Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASTOP2: Second TKI Stop in CML
NCT03573596Phase 2Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2018
- Primary completion
- Feb 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Amsterdam University Medical Center. Primary endpoint: Successful MMR maintenance at 1 year. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03573596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573596.